The clinical and laboratory findings of the 389 participants revealed a high prevalence of obesity (180, 46.3%), prostate enlargement (383, 98.5%), and elevated prostate-specific antigen (PSA) levels (233, 59.9% ± 10 ng/mL). This evidence concerns the gene KLK3 and obesity disorder.